This guidance provides clarification on the NICE Improving Outcomes Guidance for Haematological Oncology (2003), in relation to the requirement to develop integrated laboratories for the diagnosis of haematological malignancy.
Also of interest
-
Gene therapy in sickle cell and thalassaemia – where cutting-edge science meets clinical need
What does the approval for human use of new gene editing techniques mean for patients?